Dermapharm Holding SE (ETR:DMP)
Germany
· Delayed Price · Currency is EUR 35.05
-0.15 (-0.43%)
May 21, 2025, 5:35 PM CET
Dermapharm Holding SE Revenue
Dermapharm Holding SE had revenue of 310.51M EUR in the quarter ending March 31, 2025, with 3.02% growth. This brings the company's revenue in the last twelve months to 1.20B, up 5.15% year-over-year. In the year 2024, Dermapharm Holding SE had annual revenue of 1.20B with 3.89% growth.
Revenue (ttm)
1.20B
Revenue Growth
+5.15%
P/S Ratio
1.58
Revenue / Employee
331.36K
Employees
3,610
Market Cap
1.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.20B | 44.72M | 3.89% |
| Dec 31, 2023 | 1.15B | 110.19M | 10.59% |
| Dec 31, 2022 | 1.04B | 80.46M | 8.38% |
| Dec 31, 2021 | 960.09M | 151.78M | 18.78% |
| Dec 31, 2020 | 808.31M | 93.94M | 13.15% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.14B |
| Merck KGaA | 21.32B |
| Fresenius SE & Co. KGaA | 22.13B |
| Bayer Aktiengesellschaft | 46.58B |
| Fresenius Medical Care AG | 19.49B |
| Sartorius Aktiengesellschaft | 3.44B |
| Carl Zeiss Meditec AG | 2.17B |
| Fielmann Group AG | 2.33B |
Dermapharm Holding SE News
- 6 days ago - Dermapharm Hits Q1 Targets, Reaffirms 2025 Outlook - Wallstreet:Online
- 5 weeks ago - EQS-PVR: Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 6 weeks ago - EQS-DD: Dermapharm Holding SE: Susanne Gertrud Pia Lanz, buy - Wallstreet:Online
- 7 weeks ago - Dermapharm's 2024: Revenue Soars, Surpassing EBITDA Expectations - Wallstreet:Online
- 7 weeks ago - EQS-News: Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance - Wallstreet:Online
- 2 months ago - EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy - Wallstreet:Online
- 2 months ago - Dermapharm Surpasses EBITDA Forecast with Revenue Boost - Wallstreet:Online
- 2 months ago - EQS-News: Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA - Wallstreet:Online